- CEO
- Hoon-Taek Kim
- Full Time Employees
- 67
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Seongnam-si South Korea
- IPO Date
- Dec 22, 2019
- Business
- TiumBio Co., Ltd. is a South Korea-based clinical-stage biopharmaceutical company that engages in the discovery, research, and development of innovative small-molecule and biological therapeutics for rare, incurable, and underserved medical conditions. Founded in 2016 and headquartered in Seongnam, South Korea, the company specializes in therapeutics targeting immuno-oncology, gynecology, fibrosis, and hematological disorders. TiumBio operates through its core drug discovery platforms and biopharmaceutical service units, offering a pipeline of investigational assets and contract services that includes Merigolix (TU2670), an orally active, once-daily gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of endometriosis, uterine fibroids, and assisted reproductive technology; Tosposertib (TU2218), an oral dual inhibitor targeting transforming growth factor-beta receptor 1 (TGF-beta R1) and vascular endothelial growth factor receptor 2 (VEGFR2) designed to modulate the tumor microenvironment in solid tumors such as head and neck squamous cell carcinoma, biliary tract cancer, and colorectal cancer; TU7710, a recombinant activated factor VII (rFVIIa) utilizing transferrin-fusion technology engineered as a long-acting bypassing agent for hemophilia A and B patients who have developed neutralizing inhibitors; discovery-stage programs focused on pulmonary fibrosis, non-alcoholic steatohepatitis, and autoimmune diseases; and specialized Chemistry, Manufacturing, and Controls (CMC) development, process optimization, and analytical testing services delivered through its biopharmaceutical Contract Development and Analysis Organization (CDAO) subsidiary, Protium Science Co., Ltd. The company also maintains a research subsidiary, Initium Therapeutics, located in Boston, Massachusetts, to develop antibody-based therapies. In recent operational and strategic developments, TiumBio has advanced several lead candidates through international clinical partnerships and licensing transactions, including an exclusive development and commercialization agreement with Hansoh Pharmaceutical Group Co., Ltd. for Merigolix in Greater China; a clinical collaboration and supply agreement with Merck & Co., Inc. (MSD) to evaluate Tosposertib in combination with pembrolizumab (Keytruda) in Phase 2 clinical trials; and a co-development partnership with Daewon Pharmaceutical Co., Ltd. for domestic clinical trials in uterine fibroids. Furthermore, the company has completed Phase 2 clinical testing for Merigolix in uterine fibroids, advanced TU7710 into Phase 1b clinical trials, reported interim Phase 2a response data for Tosposertib in recurrent or metastatic solid tumors, and implemented strategic capital reallocations and private financings to accelerate its clinical-stage pipeline toward global licensing opportunities.